BHW Bayerische Heilmittel Wissenschaften GmbH (Germany) and NAH – North American Heilmittel Inc. (Canada) are proud to announce their merger under a single identity: the Heilmittel Group.
This strategic consolidation unites the strengths of both companies to create a truly international life sciences organization. By combining German precision and scientific excellence with North American reach and regulatory expertise, Heilmittel Group is positioned to deliver trusted healthcare and wellness solutions across global markets.
As part of the new structure:
- BHW will continue to serve as the central hub for corporate governance, research, and operations from its headquarters in Munich, supported by the new office in Frankfurt’s Omniturm.
- NAH will take responsibility for the North American and Latin American markets, while also leading the commercialization of certain product lines in the Middle Eastern and Southeast Asian markets.
The formation of Heilmittel Group allows us to:
- Operate under a unified structure, combining scientific development, international distribution, and regulatory affairs.
- Expand our ability to manage diverse product portfolios while aligning with regional market needs.
- Strengthen relationships with distributors, investors, and healthcare partners worldwide under a consistent and trusted brand.
The merger marks an important milestone — one that positions Heilmittel Group as a future-ready organization, rooted in originality, trust, and measurable impact, while expanding its global footprint across Europe, the Americas, the Middle East, and Asia.